http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2402315-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96ec3985e3ce9b24614fb87bf51a4f12 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2799-025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-002 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0066 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 |
| filingDate | 2008-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0baf08f1eec9932eac15d3747106d499 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc2986a397b2bc7b9876fa8ee0151d26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e6bbf584e02c286f1cd5327a0dce1c1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcd00e9b18d4fe9e6a0e44ff75eb058d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db59de89772e3677c374c3a145eceb67 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8536a86250723d40ec02ba54e4f7032b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0165af985af9703a3fca13d318f86dc0 |
| publicationDate | 2013-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2402315-T3 |
| titleOfInvention | New modulating molecules for an improved regulated expression system |
| abstract | A regulated expression system comprising A regulated expression system comprising at least one vector and an activating molecule (AM), including at least one vector and an activating molecule (AM), said vector comprising: a first expression cassette comprising said vector: a first expression cassette comprising: i) a first action sequence comprising: i) a first nucleic acid sequence encoding a therapeutic molecule or nucleic acid encoding a therapeutic molecule (MT) having therapeutic activity and ii) a (MT ) having a therapeutic activity and ii) a first promoter and a first poly(A) site linked or a first promoter and a first poly(A) site operably linked to said first acid sequence nutritionally to said first nucleic acid sequence, in which that said MT can be expressed in cells, wherein said MT can be expressed in cells of a subject, and said expression or activity of ace of a subject, and said expression or activity of MT is dose-dependent and regulated or inMT is dose-dependent and regulated or inducedin the presence of a regulatory molecule (MR)inducedin the presence of a regulatory molecule (MR); and a second expression cassette comprising: ; and a second expression cassette comprising: i) a second nucleic acid sequence encoding said regulatory molecule (RIv)7 and ii) a second nucleic acid sequence encoding said regulatory molecule (RIv)7 and ii) a second promoter and a second poly(A) site operatively linked promoter and a second poly(A) site operatively linked to said second acid sequence nuclearly to said second nucleic acid sequence, wherein said MR may be expressed in saidseic, wherein said MR may be expressed in said cells and activated in the presence of a cell molecule and activated in the presence of an activating molecule (AM), thereby regulating said expactivating molecule (AM), thereby regulating said MT expression or activity, and wherein said MA is reaction or MT activity, and wherein said MA is a modified steroid receptor modulator which is a modified mifepristone (MFP) modified steroid receptor modulator, wherein e is a modified mifepristone (MFP), wherein said modified mifepristone is ring substituted said modified mifepristone is an 11-beta substituted ring selected from the group consisting of d or 11-beta selected from the group consisting of BLX-913, BLX-899, BLX -952, BLX-61 0, BLX-117 and BLX-BLX-913, BLX-899, BLX-952, BLX-61 0, BLX-117 and BLX-784 and has little or limited effect on hPR 784 and has a little or limited on human hPR. human. |
| priorityDate | 2007-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 892.